ESMO 2019 | Biomarker-directed BISCAY data: durvalumab plus targeted therapies in mUC

Thomas Powles

BISCAY (NCT02546661) is an open-label, randomized, biomarker-directed, phase 1b study of durvalumab in combination with targeted therapies in metastatic urothelial cancer. Here, Principal Investigator Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, discusses the data presented at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter